Whalesbook
Aptus Pharma Ltd has reported significant financial growth for the fiscal year ended March 31, 2026. The company's standalone revenue surged 89.59% year-over-year, reaching ₹46.71 Cr from ₹24.63 Cr in the previous fiscal year. Net profit saw a substantial increase of 49.05%, climbing to ₹4.62 Cr compared to ₹3.09 Cr in FY25.
Looking at the half-year period ending March 31, 2026, standalone revenue more than doubled, rising 117.23% year-on-year to ₹32.32 Cr. Net profit for this half-year period was ₹2.87 Cr.
This strong performance underscores Aptus Pharma's rapid growth following its Initial Public Offering (IPO). The results suggest good market acceptance for its pharmaceutical formulations and indicate improved financial health and operational efficiency, with profit growth accompanying debt reduction.
Aptus Pharma operates as a pharmaceutical marketing and distribution firm using an asset-light model. The company raised ₹13.02 crore through its IPO in September 2025, with these funds earmarked for capital expenditure and working capital needs. Established in 2010, Aptus Pharma partners with contract manufacturers to offer a diverse product portfolio.
In a move signaling management confidence, the company's board has approved a bonus share issue in a 3:2 ratio, meaning shareholders will receive three bonus shares for every two shares they hold. This is intended to increase share liquidity. Furthermore, the company has substantially reduced its long-term borrowings, from ₹2.62 Cr in FY25 to ₹0.52 Cr in FY26, strengthening its balance sheet. The full utilization of IPO funds indicates investment in growth infrastructure and operations.
However, investors are noting potential challenges in working capital management. Trade receivables have risen sharply, from ₹5.64 Cr to ₹18.76 Cr, meaning a larger portion of revenue is currently outstanding from customers. Inventories have also nearly doubled, increasing from ₹7.06 Cr to ₹13.57 Cr. This, combined with a sharp rise in total expenses mainly due to increased 'Purchases of Stock in Trade,' suggests potential difficulties in inventory turnover and cash conversion.
The Indian pharmaceutical sector is generally experiencing growth, with exports reaching $30.47 billion in FY25. While large players like Sun Pharmaceutical Industries and Divis Laboratories dominate, Aptus Pharma distinguishes itself with its asset-light distribution model, partnering with contract manufacturers.
Investors will be closely watching how Aptus Pharma manages its increased receivables and inventories to improve its working capital cycle. Continued revenue momentum and effective working capital management will be key to future performance. Further updates regarding the bonus issue record date and any management commentary on addressing the working capital increases will be crucial for assessing the company's outlook.